Novo Nordisk to assert obesity market dominance with new and improved version of Wegovy
Novo Nordisk is preparing a counter-attack on Eli Lilly in the ever-growing US market for obesity treatment, where the Danish company is losing ground, according to Danish media Finans.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.